Huateng Bio Completes Tens of Millions RMB Series B Financing to Accelerate High-Quality Development of Large Animal Preclinical CRO Platform

VCBeat has learned that Guangzhou Huateng Biomedical Technology Co., Ltd. (hereinafter referred to as “HUA TENG”) has announced the successful completion of its Series B financing, amounting to tens of millions of yuan. This round of financing was supported byGuangzhou Jinkong FundandTianhe Fundstrong support, marking another round of financing from renowned institutions for HUA TENG following the completion of its Series A+ funding in 2023. To date, the company has secured cumulative financing of nearly RMB 100 million.

The funds raised in this offering will be primarily used to advance the construction of a large animal model library, enhance preclinical CRO service capabilities, further expand market presence and brand building, accelerate the R&D of innovative drugs and medical devices, and facilitate the commercialization of clients’ scientific research achievements.

Huateng Biomedical, located in Huangpu District, Guangzhou, is a national high-tech enterprise specializing in contract research organization (CRO) services for biopharmaceuticals. Led by academicians, its core team comprises senior scientists from top universities, research institutions, and enterprises both domestically and internationally. The company focuses on gene-edited large animal models (miniature pigs and rabbits), offering services that span scientific research, innovative drug development, and preclinical efficacy and safety evaluations of medical devices.

The Company is now qualified to produce a wide variety of large laboratory animals, maintains a resource library of over 200 animal models, and operates multi-platform R&D service centers, making it one of the larger one-stop preclinical R&D service providers in the Guangdong-Hong Kong-Macao Greater Bay Area.

HUA TENG Laboratory: Total Building Area Exceeds 10,000 m²², headquartered in Guangzhou, with subsidiaries in Shenzhen, Foshan, Chongqing, and Jiangsu. The company has invested nearly RMB 100 million in high-end laboratory and research equipment, establishing platforms for pharmacodynamic and pharmacokinetic evaluation, safety assessment, interventional surgery, general surgery, medical imaging, biological sample analysis and testing, and biocompatibility testing.

The Company has been honored with titles such as “National High-Tech Enterprise” and “Specialized, Refined, Differential, and Innovative (SRDI) Enterprise.” It holds licenses for the use and production of laboratory animals, has achieved defect-free accreditation by AAALAC International, maintains over 300 CMA/CNAS-certified test items, and complies with the U.S. FDA Good Laboratory Practice (GLP) regulations.

HUA TENG has facilitated the successful IND filings of over 200 innovative drugs and medical devices worldwide, with more than 2,000 research services achieving commercial translation. Upholding its mission and vision to “build a new R&D ecosystem and serve the broader healthcare industry,” the company is dedicated to providing global biomedical R&D institutions with exceptional integrated solutions.

Xie Shuilin, Founder of HUA TENG“The journey is long and arduous, but perseverance leads to success; with unwavering commitment, the future holds great promise.” We extend our sincere gratitude to Guangzhou Jinkong Fund Management Co., Ltd. and Tianhe Fund for their recognition and support. Our team has accumulated extensive expertise in scientific research services, innovative drug development, and preclinical efficacy and safety evaluation of medical devices, establishing a specialized technical service platform with distinct advantages. This platform has facilitated the successful Investigational New Drug (IND) applications for over 200 innovative drugs and medical device products worldwide, while enabling the commercial translation of more than 2,000 scientific research projects. Currently, HUA TENG has become a leading preclinical R&D service provider in the Guangdong-Hong Kong-Macao Greater Bay Area, equipped with comprehensive qualifications for large-scale experimental animal production, a repository of over 200 animal model resources, and multi-platform R&D service centers. Looking ahead, we remain committed to our mission and vision of “building a new R&D ecosystem to serve the broader healthcare industry,” striving to deliver exceptional integrated solutions to global biopharmaceutical R&D institutions.

Nie Huiming, Head of Biomedical Investment at Guangzhou Jinkong FundMr. [Name] stated: “HUA TENG has earned broad market recognition by leveraging its professional standing and innovative capabilities, achieving remarkable counter-trend growth despite a challenging macroeconomic environment. With the rapid development of the pharmaceutical and healthcare industry, preclinical CRO services, as a critical bridge connecting R&D with the market, are becoming increasingly important. HUA TENG boasts extensive experience in the preclinical evaluation of pharmaceuticals and medical devices, having established a comprehensive service system that provides robust support to numerous enterprises. Our investment in HUA TENG is driven not only by its industry-leading position but also by the potential of its team and its sustained commitment to innovation. We believe this investment will help further strengthen HUA TENG’s R&D capabilities, expand its service scope, and enhance service quality, thereby achieving mutual benefits for both parties.”

Guangzhou Financial Holdings Group Co., Ltd. is a state-owned financial holding platform established by the Guangzhou Municipal Committee of the Communist Party of China and the Guangzhou Municipal People's Government through the integration of municipal financial assets. It has become the local financial holding group with the largest asset scale, the highest credit rating, and the most comprehensive financial licenses in China, serving as a key driver for achieving high-quality economic development in Guangzhou. As of the end of June 2023, the Group’s total assets amounted to RMB 881.864 billion. It holds international credit ratings of A- from Fitch Ratings and BBB+ from S&P Global Ratings, representing the highest credit rating among domestic local financial holding groups, and ranked 258th on the 2023 Top 500 Chinese Service Enterprises list.

Guangzhou Tianhe District Investment Fund Management Co., Ltd. (hereinafter referred to as “Tianhe Fund”) was established on December 28, 2016. It is a private equity investment fund management company jointly funded by Guangzhou Jinkong Fund Management Co., Ltd. and Guangzhou Tianhe Investment Management Co., Ltd., representing the municipal and district-level governments, respectively. On August 7, 2017, it obtained registration as a private investment fund manager with the Asset Management Association of China. Over the past seven years of operation, the company has focused its investments on national strategic emerging industries, including next-generation information technology, artificial intelligence, data elements, biotechnology and healthcare, and high-end manufacturing in Tianhe District.